We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences (EW) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Edwards Lifesciences (EW - Free Report) closed at $96.03 in the latest trading session, marking a +1.37% move from the prior day. This change outpaced the S&P 500's 0.07% loss on the day. Elsewhere, the Dow gained 0.27%, while the tech-heavy Nasdaq added 0.02%.
Coming into today, shares of the medical device maker had lost 6.07% in the past month. In that same time, the Medical sector lost 5.47%, while the S&P 500 lost 7.99%.
Edwards Lifesciences will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.64, unchanged from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.4 billion, up 1.92% from the year-ago period.
EW's full-year Zacks Consensus Estimates are calling for earnings of $2.57 per share and revenue of $5.72 billion. These results would represent year-over-year changes of +15.77% and +9.29%, respectively.
Investors might also notice recent changes to analyst estimates for Edwards Lifesciences. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% higher. Edwards Lifesciences is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, Edwards Lifesciences is holding a Forward P/E ratio of 36.92. This valuation marks a premium compared to its industry's average Forward P/E of 27.19.
Also, we should mention that EW has a PEG ratio of 2.66. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 1.92 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 162, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Edwards Lifesciences (EW) Gains As Market Dips: What You Should Know
Edwards Lifesciences (EW - Free Report) closed at $96.03 in the latest trading session, marking a +1.37% move from the prior day. This change outpaced the S&P 500's 0.07% loss on the day. Elsewhere, the Dow gained 0.27%, while the tech-heavy Nasdaq added 0.02%.
Coming into today, shares of the medical device maker had lost 6.07% in the past month. In that same time, the Medical sector lost 5.47%, while the S&P 500 lost 7.99%.
Edwards Lifesciences will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.64, unchanged from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.4 billion, up 1.92% from the year-ago period.
EW's full-year Zacks Consensus Estimates are calling for earnings of $2.57 per share and revenue of $5.72 billion. These results would represent year-over-year changes of +15.77% and +9.29%, respectively.
Investors might also notice recent changes to analyst estimates for Edwards Lifesciences. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% higher. Edwards Lifesciences is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, Edwards Lifesciences is holding a Forward P/E ratio of 36.92. This valuation marks a premium compared to its industry's average Forward P/E of 27.19.
Also, we should mention that EW has a PEG ratio of 2.66. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 1.92 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 162, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.